DGAP-Adhoc: Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic
DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Contact for investors and press
[1] Currency-adjusted sales growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
29-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | Carl Zeiss Meditec AG |
Göschwitzer Str. 51-52 | |
07745 Jena, Germany | |
Germany | |
Phone: | +49 (0)3641 220-0 |
Fax: | +49 (0)3641 220-112 |
E-mail: | [email protected] |
Internet: | www.zeiss.de/meditec-ag/ir |
ISIN: | DE0005313704 |
WKN: | 531370 |
Indices: | MDAX, TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1144021 |
End of Announcement | DGAP News Service |
|
1144021 29-Oct-2020 CET/CEST
Carl Zeiss Meditec AG Aktie
Die Carl Zeiss Meditec AG Aktie spaltet die Meinungen: Gleichstand zwischen Buy- und Sell-Einschätzungen.
Ein Kursziel von 122 € für Carl Zeiss Meditec AG würde eine Steigerung von mehr als 50% gegenüber dem aktuellen Kurs von 64.1 € bedeuten.